[Form 4] Alerus Financial Corporation Insider Trading Activity
Rhea-AI Filing Summary
Alerus Financial Corp. (ALRS) Form 4: EVP & CFO Alan Villalon reported an open-market purchase of company stock.
- Date of transaction: 07/31/2025
- Shares acquired: 2,350 common shares
- Purchase price: $21.21 per share
- Direct ownership after trade: 10,587 shares
- Indirect ownership: 672.8807 shares held via the Alerus Financial Corporation Employee Stock Ownership Plan (ESOP), reflecting allocations since the prior report
- Derivative securities: None reported
The filing, signed 08/04/2025, shows the CFO increasing his personal stake, which can signal confidence in ALRS’s prospects. No sales or other dispositions were disclosed.
Positive
- CFO insider purchase: 2,350 shares acquired at $21.21, increasing direct ownership to 10,587 shares.
- No dispositions or derivatives: Filing shows only buying activity, reinforcing a confidence signal.
Negative
- None.
Insights
TL;DR: CFO bought 2,350 ALRS shares, lifting direct stake to 10,587—insider buying is typically viewed as a positive signal.
Open-market insider purchases often indicate management’s conviction that shares are undervalued or future prospects are strong. The $21.21 purchase price represents real cash commitment and adds roughly $50k to the CFO’s exposure. The absence of any simultaneous sales or hedging derivatives strengthens the bullish optics. While the dollar amount is modest relative to ALRS’s market cap, investors may interpret the action as incremental confirmation of management confidence.
TL;DR: Transaction is straightforward, complies with Section 16 reporting; no governance red flags detected.
The Form 4 supplies timely disclosure, includes Rule 10b5-1 checkbox (left unchecked), and specifies that the ESOP allocations are routine. No derivative grants or complex structures were used, reducing opacity for shareholders. From a governance standpoint, insider buying—especially by a C-suite officer—aligns interests with shareholders and is generally welcomed unless followed by rapid sales or equity grants, none of which are indicated here.